Is LeonaBio, Inc. (LONA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.5% / 30% | 103.6% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 2.5% / 33% | 103.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.1% / 33% | 87.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.5% / 33% | 103.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.1% / 33% | 87.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -89.4% | |
| Return on Assets (ROA) | -42.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$97M |
| Free Cash Flow | -$97M |
| Total Debt | $1M |
| Debt-to-Equity | 3.4 |
| Current Ratio | 9.7 |
| Total Assets | $59M |
Price & Trading
| Last Close | $9.68 |
| 50-Day MA | $6.31 |
| 200-Day MA | $4.81 |
| Avg Volume | 84K |
| Beta | 2.8 |
|
52-Week Range
$2.20
| |
About LeonaBio, Inc. (LONA)
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is LeonaBio, Inc. (LONA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), LeonaBio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is LeonaBio, Inc.'s debt ratio?
LeonaBio, Inc.'s debt ratio is 2.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.1%.
What are LeonaBio, Inc.'s key financial metrics?
LeonaBio, Inc. has a market capitalization of $84M. Return on equity stands at -89.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.